GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ultragenyx Pharmaceutical Inc (STU:UP0) » Definitions » Debt-to-Asset

Ultragenyx Pharmaceutical (STU:UP0) Debt-to-Asset : 0.03 (As of Mar. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Ultragenyx Pharmaceutical Debt-to-Asset?

Ultragenyx Pharmaceutical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €11.8 Mil. Ultragenyx Pharmaceutical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was €25.7 Mil. Ultragenyx Pharmaceutical's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Mar. 2024 was €1,202.5 Mil. Ultragenyx Pharmaceutical's debt to asset for the quarter that ended in Mar. 2024 was 0.03.


Ultragenyx Pharmaceutical Debt-to-Asset Historical Data

The historical data trend for Ultragenyx Pharmaceutical's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ultragenyx Pharmaceutical Debt-to-Asset Chart

Ultragenyx Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.03 0.03 0.03 0.02 0.03

Ultragenyx Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.02 0.02 0.04 0.03 0.03

Competitive Comparison of Ultragenyx Pharmaceutical's Debt-to-Asset

For the Biotechnology subindustry, Ultragenyx Pharmaceutical's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ultragenyx Pharmaceutical's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ultragenyx Pharmaceutical's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Ultragenyx Pharmaceutical's Debt-to-Asset falls into.



Ultragenyx Pharmaceutical Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Ultragenyx Pharmaceutical's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(11.55 + 28.036) / 1367.259
=0.03

Ultragenyx Pharmaceutical's Debt-to-Asset for the quarter that ended in Mar. 2024 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(11.759 + 25.741) / 1202.514
=0.03

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ultragenyx Pharmaceutical  (STU:UP0) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.


Ultragenyx Pharmaceutical Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Ultragenyx Pharmaceutical's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Ultragenyx Pharmaceutical (STU:UP0) Business Description

Traded in Other Exchanges
Address
60 Leveroni Court, Novato, CA, USA, 94949
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. It identifies, acquires, develops, and commercializes novel products for the treatment of serious rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. The company's medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients 1 year of age and older. Mepsevii is indicated in pediatric and adult patients for the treatment of Mucopolysaccharidosis VII.

Ultragenyx Pharmaceutical (STU:UP0) Headlines

No Headlines